WinstonWınston
Back

This stock no longer trades (delisted June 11, 2026)

Delisted / no longer publicly traded (per market data provider) Everything below is based on the last available data — treat it as historical, not a live read.

Masimo Corporation logo

Masimo Corporation

MASI
60
Medical - Devices · Healthcare
Price
$179.95
+0.00 (+0.00%)
Market Cap
$9.42B
Exchange
NASDAQ
Winston Score
60
Historical score — this stock no longer trades, so the score is frozen at the last available data.
Data as of Aug 23, 2026 · filings through Apr 4, 2026
How the score breaks down
Quality
Strong
Growth
Weak
Cash Flow
Exceptional
Stability
Strong
Valuation
Good

Share count falling — buybacks

6.0% over 5y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 57.7M (2021) → 54.2M (2026)

Winston Score History

The full picture

Masimo Corporation makes medical monitoring devices used in hospitals and clinics around the world. Its most well-known product is a pulse oximeter — a sensor that measures oxygen levels in a patient's blood without breaking the skin. Masimo's technology is used by nurses and doctors to track patients in intensive care units, operating rooms, and emergency departments.

Masimo earns money by selling its monitoring hardware and then charging hospitals ongoing fees for the disposable sensors and software that go with it — a model that creates recurring revenue. The company operates globally, with a large share of sales in the United States, and its patented Signal Extraction Technology gives it a strong edge over cheaper competitors by working accurately even when patients move or have poor circulation. A key risk is Masimo's ongoing effort to expand into consumer health wearables, which puts it in direct competition with much larger companies like Apple and has drawn significant investor scrutiny in recent years.

Politician Trades

2 trades / 12mo

0 Congressional buys and 2 sells on MASI in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades
Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
62.1%
Premium pricing power — 62.1% gross margin
Profit after running costs
Operating Margin
19.2%
Healthy — 19.2% operating margin
Return on the money invested
ROCE
24.9%
Exceptional — 24.9% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-14.4%
Shrinking sales (-14.4% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
304%
Turns 304% of profit into real cash
Spare cash per sale
FCF Margin
13.4%
Converts sales into free cash efficiently (13.4%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.57
Conservative — low debt load (0.57)
Covers its interest
Interest Cover
10.11x
Comfortably covers interest (10.1x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
125.0x
Expensive — P/E 125.0

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year
P/E vs Forward
+97.8
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (125.0 → 27.2)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial